Latest news
25 items- PRGrace Therapeutics to Participate in Upcoming Investor Events January 2025PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) formerly Acasti Pharma Inc. (NASDAQ:ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs, today announced that Chief Executive Officer Prashant Kohli will participate the following investor and industry networking events during the month of January 2025. 14th Annual LifeSci Partners Corporate Access Event – (January 13, 2025) BIO One-on-One Partnering™ – (Ja
- PRGrace Therapeutics to Exhibit at the American Society of Health-System Pharmacists ConferencePRINCETON, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) formerly Acasti Pharma Inc. (NASDAQ:ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs, today announced that the Company will be participating in the mid-year clinical meeting of the American Society of Health-System Pharmacists (ASHP) to be held December 8–12, 2024, in New Orleans, LA. "As we look forward to data readout from our Phase 3 STRIVE-ON trial
- SECAcasti Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- SECAcasti Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Acasti Pharma Inc. (0001444192) (Filer)
- PRAcasti Announces Corporate Name Change to Grace Therapeutics, Inc.Name Change Reflects Extensive Scientific and Corporate Brand Equity Previously Established under Grace Therapeutics Grace Therapeutics will begin trading on Nasdaq under the trading symbol "GRCE" effective October 28, 2024 Virtual Key Opinion Leader Event to be held on November 20th PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTx-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it is changing its name to Grace Therapeutics, Inc. (Grace Therapeutics).
- SECSEC Form EFFECT filed by Acasti Pharma Inc.EFFECT - Acasti Pharma Inc. (0001444192) (Filer)
- SECSEC Form EFFECT filed by Acasti Pharma Inc.EFFECT - Acasti Pharma Inc. (0001444192) (Filer)
- SECSEC Form S-8 filed by Acasti Pharma Inc.S-8 - Acasti Pharma Inc. (0001444192) (Filer)
- SECSEC Form S-8 POS filed by Acasti Pharma Inc.S-8 POS - Acasti Pharma Inc. (0001444192) (Filer)
- SECSEC Form S-8 POS filed by Acasti Pharma Inc.S-8 POS - Acasti Pharma Inc. (0001444192) (Filer)
- SECSEC Form S-8 POS filed by Acasti Pharma Inc.S-8 POS - Acasti Pharma Inc. (0001444192) (Filer)
- SECSEC Form POS AM filed by Acasti Pharma Inc.POS AM - Acasti Pharma Inc. (0001444192) (Filer)
- SECSEC Form POS AM filed by Acasti Pharma Inc.POS AM - Acasti Pharma Inc. (0001444192) (Filer)
- SECAcasti Pharma Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Acasti Pharma Inc. (0001444192) (Filer)
- SECAcasti Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Acasti Pharma Inc. (0001444192) (Filer)
- PRAcasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that patient enrollment has been completed in the Company's Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405). The STRIVE-ON trial is a prospective, open-label, randomized (1:1 ratio), parallel group trial of GTX-104 compared with oral nimodipine, in 100 patients hospitalized for aSAH. Approximately 25 hospitals in the U.S. are participating. "We are ex
- PRAcasti to Present at the Life Sciences Investor ForumPRINCETON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that Prashant Kohli, Chief Executive Officer of Acasti, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19th 2024. To register for the event and access the Acasti presentation webcast, click on the link below. Life Sciences Investor Forum Date: September 19, 2024 Time: 12:30 PM EDT O
- SECSEC Form DEFA14A filed by Acasti Pharma Inc.DEFA14A - Acasti Pharma Inc. (0001444192) (Filer)
- PRAcasti to Participate in the H.C. Wainwright 26th Annual Global Investment ConferencePRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference, to be held September 9th – 11th in New York, NY. Prashant Kohli, Chief Executive Officer of Acasti, will be available for one-on-meetings on September 9th and 10th. H.C. Wainwright 26th Annual Global Investment Conference Title: Acasti Corporate Presentation P
- SECAcasti Pharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Acasti Pharma Inc. (0001444192) (Filer)
- SECAcasti Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Acasti Pharma Inc. (0001444192) (Filer)
- PRAcasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business UpdateSurpassed 50% Enrollment Milestone in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with NDA Submission on Track for 1H Calendar 2025Projected Cash Runway into Second Calendar Quarter 2026 PRINCETON, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial results and business highlights for the quarter ended June 30,
- SECSEC Form 10-Q filed by Acasti Pharma Inc.10-Q - Acasti Pharma Inc. (0001444192) (Filer)
- SECSEC Form 424B3 filed by Acasti Pharma Inc.424B3 - Acasti Pharma Inc. (0001444192) (Filer)
- SECSEC Form EFFECT filed by Acasti Pharma Inc.EFFECT - Acasti Pharma Inc. (0001444192) (Filer)
ACST FAQ
6 questionsWhat does Acasti Pharma Inc. do?
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.Where does ACST stock trade?
Acasti Pharma Inc. (ACST) is listed on NASDAQ.What sector and industry is ACST in?
Acasti Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ACST?
Acasti Pharma Inc. has had 2 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $600.00 price target on 2021-12-22. Recent price targets cluster around $600.00.What companies are similar to ACST?
Notable peers in the same industry include MEIP (MEI Pharma Inc.), HUGE (FSD Pharma Inc.), HOOK (HOOKIPA Pharma Inc.). Compare ACST side-by-side with any of them on Quantisnow.How can I track ACST on Quantisnow?
Quantisnow aggregates Acasti Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACST to receive live email and push alerts on every new disclosure.